You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Deerfield, Illinois – October 25, 2007 – Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL® (conivaptan hydrochloride injection) effectively raises serum sodium...
BASEL, Switzerland & MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 22, 2007--Roche and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been approved in Japan for...
Read more about Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued...
Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...
Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....
Read more about OSI Pharmaceuticals Provides Additional Information about US Sales of Tarceva
DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...
Read more about OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...
CHICAGO--(BUSINESS WIRE)--June 5, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company's lead product, Tarceva®, presented...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding...
Follow U.S. news
